FDA declines to endorse leucovorin for autism, approves it for cerebral folate deficiency
CNN6 days
FDA Approves Leucovorin for Rare Genetic Brain Disorder
Is the FDA's approval of leucovorin a milestone for patients or a debacle following unproven autism claims?
Above: The FDA's White Oak campus in Silver Spring, Maryland, on July 17, 2025. Image credit: ISSAM AHMED/AFP /Getty Images
The Spin
Pro-establishment narrative
The FDA's approval of leucovorin for cerebral folate deficiency marks a significant milestone for patients with this rare genetic condition who previously had no treatment options to turn to. The groundbreaking decision is yet another example of the FDA's commitment to addressing the critical needs of individuals who are suffering from severe neurological complications.
Establishment-critical narrative
The administration's handling of leucovorin has been a total debacle. After hyping it as a potential autism treatment on live television, the administration has quietly walked back its claims after admitting it lacks the evidence to support its observations. In the future, perhaps the White House should make announcements after obtaining the proof rather than before.
Metaculus Prediction
Public Figures
The Controversies
Establishment split
CRITICAL
PRO
© 2026 Improve the News Foundation. All rights reserved.Version 6.18.0
© 2026 Improve the News Foundation.
All rights reserved.
Version 6.18.0